Nordic CLL Study Group Report issue

Academic/Hospital Phase 2

Organization Overview

First Clinical Trial
2017
NCT03226301
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Nordic CLL Study Group

Active Ingredients

Drugs in Phase 2 Trials (2)

ibrutinib (imbruvica) (1 trial)

venetoclax (venclexta) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 2